PUBLISHER: The Business Research Company | PRODUCT CODE: 1946614
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946614
NGS-based RNA-sequencing is a technique employed to identify and quantify the amount of ribonucleic acid (RNA) present in a biological sample at a specific moment, utilizing next-generation sequencing (NGS). Next-generation sequencing, characterized by massively parallel sequencing technology, offers exceptionally high throughput, scalability, and speed, allowing for the determination of nucleotide sequences in whole genomes or specific DNA/RNA segments.
The primary products and services associated with NGS-based RNA sequencing include sample preparation products, sequencing platforms and consumables, sequencing services, and data analysis, storage, & management. Sample preparation products facilitate the adherence of DNA or RNA to the sequencing flowcell, enabling sample identification. The sample preparation process involves converting nucleic acid mixtures from biological samples into various libraries, preparing them for NGS technologies. Technologies involved in NGS encompass sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing. These sequencing methods find application in expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, variant calling, and transcriptome epigenetics. NGS-based RNA-sequencing is utilized by a range of end users, including research & academia, hospitals & clinics, pharmaceutical & biotechnology companies, and other entities in the scientific community.
Tariffs are impacting the NGS-based RNA-sequencing market by increasing costs of imported sequencing instruments, reagents, consumables, and data storage infrastructure. Research laboratories and biotechnology companies in North America and Europe are most affected due to dependence on imported platforms, while Asia-Pacific faces cost pressure on sequencing services. These tariffs are increasing operational costs and slowing technology upgrades. However, they are also encouraging domestic instrument manufacturing, regional reagent production, and development of localized sequencing service providers.
The ngs-based rna-sequencing market research report is one of a series of new reports from The Business Research Company that provides ngs-based rna-sequencing market statistics, including ngs-based rna-sequencing industry global market size, regional shares, competitors with a ngs-based rna-sequencing market share, detailed ngs-based rna-sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the ngs-based rna-sequencing industry. This ngs-based rna-sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ngs-based rna-sequencing market size has grown exponentially in recent years. It will grow from $4.2 billion in 2025 to $5.27 billion in 2026 at a compound annual growth rate (CAGR) of 25.3%. The growth in the historic period can be attributed to expansion of genomic research initiatives, declining cost of sequencing technologies, increased use of rna-seq in academic research, availability of advanced sequencing platforms, growth of bioinformatics capabilities.
The ngs-based rna-sequencing market size is expected to see exponential growth in the next few years. It will grow to $12.73 billion in 2030 at a compound annual growth rate (CAGR) of 24.7%. The growth in the forecast period can be attributed to increasing adoption of rna sequencing in clinical diagnostics, rising investments in precision medicine, expansion of pharmaceutical research applications, growing demand for integrated data analysis solutions, increasing focus on multi-omics research. Major trends in the forecast period include increasing adoption of high-throughput rna sequencing platforms, rising demand for single-cell rna sequencing, growing use of cloud-based bioinformatics analysis, expansion of transcriptomics in precision medicine, enhanced focus on data accuracy and scalability.
The expanding pharmaceutical industry is anticipated to support the continued growth of the NGS-based RNA-sequencing market. The pharmaceutical industry encompasses the research, development, and manufacturing of drugs and medicines by both public and private organizations. Within this sector, NGS-based RNA-sequencing is widely used to perform comprehensive gene expression analysis, identify and validate potential drug targets, evaluate drug responses, and gain deeper insights into disease biology, thereby supporting more efficient and data-driven drug discovery and development. For example, in November 2024, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, North America accounted for 54.8% of global pharmaceutical sales in 2024, while Europe represented 22.7%. As a result, the expansion of the pharmaceutical industry is contributing significantly to the growth of the NGS-based RNA-sequencing market.
Leading companies active in the NGS-based RNA-sequencing market are increasingly concentrating on the development of innovative offerings such as advanced small RNA-sequencing kits to simplify workflows and enhance the precision and efficiency of RNA expression studies. These advanced small RNA-seq kits are next-generation library preparation solutions engineered to accurately capture and sequence small RNA molecules, enabling researchers to shorten processing times, reduce technical artifacts such as adapter dimers, and generate more consistent and reproducible expression data. For instance, in October 2025, Lexogen, an Austria-based biotechnology company, introduced the miRVEL Profiling Small RNA-Seq Library Prep Kit, which is designed to streamline and optimize small RNA research workflows. The kit enables the preparation of ready-to-sequence libraries in less than seven hours with limited hands-on time, incorporates advanced adapter-blocking technology to minimize adapter dimer formation, delivers reproducible performance across a wide range of input amounts, and includes integrated 8-nucleotide unique dual indices for accurate multiplexing and read assignment. The miRVEL Profiling Kit supports diverse applications such as RNA interference research, studies of host defense mechanisms, and plant and agricultural small RNA analysis, and is compatible with Lexogen's SPLIT RNA extraction kits and TraPR small RNA enrichment system, offering a comprehensive end-to-end solution for small RNA sequencing.
In November 2024, ARCHIMED SAS, a France-based private equity firm, acquired SeqCenter LLC for an undisclosed consideration. Through this acquisition, ARCHIMED sought to enhance its diagnostics and life-science tools portfolio by expanding SeqCenter's next-generation sequencing capabilities, accelerating international growth, and promoting innovation in high-throughput and cost-efficient DNA and RNA sequencing services. SeqCenter LLC is a United States-based genetic sequencing services provider specializing in fast, reliable, and affordable DNA and RNA sequencing solutions for use across research, biotechnology, diagnostics, agriculture, and environmental health applications.
Major companies operating in the ngs-based rna-sequencing market are Illumina Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies Ltd., Agilent Technologies Inc., BGI Group, QIAGEN N.V., Eurofins Scientific SE, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Takara Bio Inc., GENEWIZ Inc., Novogene Corporation, Macrogen Inc., Zymo Research Corp., Lexogen GmbH, Partek Incorporated, GATC Biotech AG, Genohub LLC, BaseClear B.V., Otogenetics Corporation, SeqLL LLC, GenXPro GmbH, Genotypic Technology Pvt. Ltd.
North America was the largest region in the NGS-based RNA sequencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngs-based rna-sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the ngs-based rna-sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The NGS-based RNA-sequencing market includes revenues earned by ribosomal RNA (rRNA), transfer RNA (tRNA), long ncRNA and many smaller ncRNAs such as microRNA. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
NGS-Based RNA-Sequencing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses ngs-based rna-sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for ngs-based rna-sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ngs-based rna-sequencing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.